ARTICLE SUMMARY:
Heart failure isn’t just a failing heart—it’s a system in revolt, where heart, lungs, kidneys, lymphatics, and blood vessels conspire to fuel decline. Next-gen heart failure start-ups tap into physiological mechanisms to bring order back to the system.
Heart failure still represents one of the greatest unmet needs in medicine. The lifetime risk of this degenerative and life-threatening disease has risen to almost one in four, and according to the Heart Failure Society of America’s “HF Stats 2025: Heart Failure Epidemiology and Outcomes Statistics,”in the US approximately 6.7 million people over the age of 20 have heart failure. That prevalence is rapidly rising.
In 2022, heart failure was a contributing cause of almost half of all cardiovascular deaths, and within two decades, the costs of managing this challenging condition are projected to reach $858 billion, with 50% of that sum due to frequent episodes of hospitalization.
Long seen by therapy innovators as primarily a problem of the heart’s pumping—mechanical and electrical dysfunctions that could be fixed in isolation—today’s heart failure innovators understand it as a systemic condition: a complex interplay between the heart, lungs, kidneys, lymphatic system, and vasculature, where each component can amplify—or worsen—the others in a doom loop.
